Clearblue has introduced a new product, the “Menopause Stage Indicator,” designed to identify the specific stage of menopause a user is experiencing. Resembling their renowned pregnancy test stick, this innovative device tests for follicle-stimulating hormone (FSH) in urine rather than pregnancy hormones. For precise results, users are advised to conduct five tests across ten days, ideally every alternate day. By assessing FSH levels, menstrual cycle patterns, and the user’s age, Clearblue can pinpoint the menopause stage, categorizing it into premenopause, early perimenopause, late perimenopause, or postmenopause.
While Clearblue emphasizes that only medical professionals can definitively diagnose a person’s menopause stage, their accompanying app allows users to generate a detailed report. This can then be shared with a healthcare provider to validate the results and explore potential treatments. The Menopause Stage Indicator will soon be available on Amazon, starting at $20.
Despite its significance, women’s health has often been sidelined within the broader healthcare sector. This neglect is even more pronounced for those transitioning into menopause. Clearblue’s venture into this niche — as a brand predominantly recognized for pregnancy tests — comes at a pivotal moment. Data reveals that a staggering 73% of women undergo menopause without seeking symptom relief, and the global menopause market is expected to soar to $21.6 billion by 2026.
